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Does Prenatal Valproate Interact with
a Genetic Reduction in the Serotonin
Transporter? A Rat Study on Anxiety
and Cognition
Bart A. Ellenbroek*, Caren August and Jiun Youn
School of Psychology, Victoria University of Wellington, Wellington, New Zealand
There is ample evidence that prenatal exposure to valproate (or valproic acid, VPA)
enhances the risk of developing Autism Spectrum Disorders (ASD). In line with this, a
single injection of VPA induces a multitude of ASD-like symptoms in animals, such as
rats and mice. However, there is equally strong evidence that genetic factors contribute
significantly to the risk of ASD and indeed, like most other psychiatric disorders,
ASD is now generally thought to results from an interaction between genetic and
environmental factors. Given that VPA significantly impacts on the serotonergic system,
and serotonin has strong biochemical and genetic links to ASD, we aimed to investigate
the interaction between genetic reduction in the serotonin transporter and prenatal
valproate administration. More specifically, we exposed both wildtype (SERT+/+) rats and
rats heterozygous for the serotonin transporter deletion (SERT+/−) to a single injection of
400mg/kg VPA at gestational day (GD) 12. The offspring, in adulthood, was assessed in
four different tests: Elevated Plus Maze and Novelty Suppressed Feeding as measures
for anxiety and prepulse inhibition (PPI) and latent inhibition asmeasures for cognition and
information processing. The results show that prenatal VPA significantly increased anxiety
in both paradigm, reduced PPI and reduced conditioning in the latent inhibition paradigm.
However, we failed to find a significant gene–environment interaction. We propose
that this may be related to the timing of the VPA injection and suggest that whereas
GD12 might be optimal for affecting normal rat, rats with a genetically compromised
serotonergic systemmay be more sensitive to VPA at earlier time points during gestation.
Overall our data are the first to investigate gene ∗ environmental interactions in a genetic
rat model for ASD and suggest that timing may be of crucial importance to the long-term
outcome.
Keywords: Autism Spectrum Disorder, latent inhibition, prepulse inhibition, novelty suppressed feeding,
gene–environment interaction, animal model, SERT Knock-out
INTRODUCTION
Autism spectrum disorder (ASD) is a pervasive developmental disorders that starts very early in life.
In fact, most cases are diagnosed before the age of 3 and many persist into adulthood. One of the
intriguing aspects of ASD is that in recent years the incidence has dramatically increased. The center
for disease control and prevention in the USA found a 4-fold increase in prevalence in the period
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between 2000 and 2010 (http://www.cdc.gov/mmwr/pdf/ss/
ss6302.pdf). Similar increases have also been reported in other
countries, including Denmark (Hansen et al., 2015), Finland
(Kielinen et al., 2000), the UK (Baird et al., 2006) and Australia
(Williams et al., 2008). While the reasons for this increase are still
hotly debated, the consequence is that the personal and economic
burden of ASD is tremendous, with annual estimates as high as
175 billion US$ for the USA (Buescher et al., 2014).
Although deficits in social communication and interaction
and increased repetitive and stereotyped behaviors are at the core
of ASD, the majority of patients suffer from a large number of
additional symptoms (Levy et al., 2009), including depression,
anxiety, and cognitive deficits. While most animal modeling
research has concentrated on the core symptoms, much less
attention has been paid to these co-morbidities, in spite of the
fact that they represent a substantial part of the clinical burden.
For that reason, in this paper we aim to investigate anxiety-like
symptoms and cognitive deficits in a new animal model for ASD.
Most animal models for ASD have been based on genetics
(Moy et al., 2007, 2008). Indeed, a review of the SFARI (Simons
Foundation Autism Research Initiative) database identified more
than 70 different genetic mouse models for ASD (Banerjee-Basu
and Packer, 2010). This strong focus on genetic models is not
surprising given the fact that ASDwas long thought to have a very
high (up to 90%) heritability (Lecouteur et al., 1996). However,
more recent studies have challenged this view and suggest that
the heritability is closer to 50%, more similar to most other
psychiatric disorders (Gauglerl et al., 2014; Sandin et al., 2014). In
line with this, several (early) environmental challenges have been
shown to enhance the risk of developing ASD, including prenatal
stress (Kinney et al., 2008b), prenatal infections (Atladottir et al.,
2010; Abdallah et al., 2012), and prenatal exposure to specific
drugs, such as selective serotonin reuptake inhibitors (SSRI)
(Man et al., 2015) or valproate (valproic acid, VPA) (Christensen
et al., 2013). Although the risk of SSRIs inducing ASD is still
controversial (Malm et al., 2016), the evidence that the mood-
stabilizing and anti-epileptic drug valproate increases the risk
of ASD is much stronger (Moore et al., 2000; Rasalam et al.,
2005; Bromley et al., 2008; Roullet et al., 2013). For instance,
in one of the most recent, large-scale, population-based studies
conducted in Denmark, 4.4% of individuals prenatally exposed to
VPA developed ASD, compared to 1.5% of controls not exposed
to VPA - indicating a near 3-fold increased risk for ASD in
those prenatally exposed to VPA (Christensen et al., 2013). In
line with these findings, studies in rats and mice have shown
that prenatal exposure of VPA [usually a single injection on
gestational day (GD) 12] induces increases in repetitive behaviors
and disruptions of social behavior (Schneider and Przewlocki,
2005; Ranger and Ellenbroek, 2015).
In contrast to the large number of animal models based
on either genetic or environmental factors there is a dearth
of animal models investigating an interaction between these
two factors, in spite of the clinical evidence in favor of such
interactions (Kim and Leventhal, 2015). In particular, several
studies have investigated how the genetic risk of a variation in
the serotonin transporter (SERT) is moderated by environmental
factors. Serotonin (5-HT) has long been implicated in ASD,
with high peripheral levels of 5-HT being one of the most
replicated biochemical findings (Lam et al., 2006). In addition,
reduced levels of SERT and 5-HT2A receptors have repeatedly
been found in drug naïve patients (Zurcher et al., 2015). Genetic
studies investigating the serotonergic system and especially the
SERT have been less consistent, although several studies have
suggested that genetic alterations, such as the 9/10 repeat of the
STin2 and the s-allele of the 5-HTTLPR (5-Hydroxytryptamine
transporter linked polymorphic region) may be linked to ASD
(Nyffeler et al., 2014; Warrier et al., 2015). Several reasons
for this inconsistency have been proposed including genetic
heterogeneity of ASD and the possibility that these genetic
variants are only related to specific (subsets of) symptoms. In
addition, most genetic linkage studies have ignored the potential
interaction with environmental factors. Indeed two recent studies
showed that while the s-allele of the 5-HTTLPR by itself did
not constitute a significant risk factor for ASD or ASD-like
symptoms, the risk was significantly enhanced in combination
with prenatal smoking or stress (Nijmeijer et al., 2010; Hecht
et al., 2016).
Interestingly, the s-allele of the 5-HTTLPR has also been
associated with anxiety (Kenna et al., 2012) and cognitive
deficits (Weiss et al., 2014), which are also prominent in
patients with ASD, as mentioned above. Since prenatal valproate
significantly affects serotonergic neurotransmission (Miyazaki
et al., 2005; Oyabu et al., 2013), the present study investigates the
potential interaction between valproate and a genetic reduction
of the SERT. More specifically, we injected heterozygous SERT
knock-out and wildtype rats prenatally with a moderate dose
(400mg/kg s.c.) of valproate and investigated the behavior of
the offspring in two models for anxiety (elevated plus maze and
novelty suppressed feeding) and two models assessing cognition
and information processing (latent inhibition and prepulse
inhibition). To our knowledge, this study is the first which
combined two well known risk factors in a rat model of autism.
Given the high prevalence of the risk SERT polymorphism in
the general population and the wide spread use of valproate for
various conditions in pregnantmothers (Christensen et al., 2013),
the relevance for our study stands to be considerable.
MATERIALS AND METHODS
Animals
The SERT knock-out (Slc6a41Hubr SERT−/−) rats were originally
developed by us using ENU mutagenesis in Wistar rats (Smits
et al., 2006; Homberg et al., 2007a). In the present study male
and female SERT+/− rats were mated overnight and the presence
of a vaginal plug the next morning was taken as a sign of
successful conception and counted as Gestational Day 1 (GD1).
On GD12.5, half of the pregnant females were subcutaneously
injected with 400 mg/kg of VPA (valproic acid, Sigma-Aldrich,
Auckland, NZ) with the remaining half injected with saline 1
ml/kg. The dose of VPA was based on pilot studies in our own
laboratory showing that this dose produced moderate effects on
anxiety in normal wild-type animals. Moreover, the dose is in
line with other previously published reports (Kim et al., 2011),
although higher doses (up to 800mg/kg) have also been used
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(Schneider et al., 2008; Dufour-Rainfray et al., 2010; Bambini-
Junior et al., 2011; Oyabu et al., 2013; Raza et al., 2015). However,
it is important to realize that we aimed to induce only moderate
effects in wildtype animals so as to be able to observe a gene ∗
environment interaction without the risk of inducing a ceiling
effect. The treatment led to six different groups of offspring,
of which only four were used: VPA/SERT+/−, VPA/SERT+/+,
SAL/SERT+/−, and SAL/SERT+/+. Given that ASD is much
more common in males than in females, only male offspring
were used for this study. The rats were weaned at 21 days of
age when a small ear punch (2mm diameter) was taken for
genotyping (genotyping was performed by Transnetyx, Cordova,
USA). Males were housed in groups of 2–4 in standard housing
cages in the animal facility of the School of Psychology, Victoria
University of Wellington facilities. Rooms were humidity (77%)
and temperature (21◦C) controlled and kept on 12 h light/dark
cycles (lights on 07:00 a.m.). The animals had free access to
food and water except during the novelty suppressed feeding
(in preparation for which they were deprived of food for 24 h
prior to the experiment, see below) and the latent inhibition
experiment (during which water intake was restricted, see below).
All experiments were performed in adulthood (>postnatal day
60) with experimentally naïve animals. Animals from at least 4
different litters were used for every experiment to prevent any
possible litter effect. All experiments were in accordance with
institutional and national guidelines and were approved by the
animal ethics committee of Victoria University Wellington.
Elevated Plus Maze
The elevated plus maze (EPM) consisted of four arms of
equal length (50 cm) and width (10 cm), with two opposing
arms enclosed by opaque walls (height 20 cm, closed arms),
and the two remaining arms only having a shallow raised
transparent (1 cm) lip (open arms). Rats were briefly handled
for 2 consecutive days prior to the start of the experiment
to habituate them to pre-test stressors. Immediately before the
EPM, rats were placed in an open field for 5 min to encourage
exploratory behavior (Pellow et al., 1985). Immediately after the
open field test, the rats were placed in one of the closed arms
and the behavior was recorded for 5 min using Ethovision XT9
(Noldus, Wageningen, the Netherlands). Oﬄine analysis was
performed to assess latency to first emerge from the entry arm,
frequency and duration in each arm as well as overall percentage
of time spent in the open and closed arms. Arm entry was
defined as the tail base point entering the arm. Total distance
traveled and velocity was also recorded, along with assessment
of the frequency and duration of the stretched attend posture,
defined as a body posture state which is over 75% of elongation
measure. Elongation is expressed as a percentage and ranges
from 0 (when the subject’s shape is perfectly circular) to 100%
(when the subject’s shape is a line). In total 67 rats were used (see
Table 1).
Novelty Suppressed Feeding
The novelty suppressed feeding (NSF) test is based on the
conflict between exposure to an open area and the drive to eat
(Olivier et al., 2008). All animals were again handled briefly
TABLE 1 | Total number of animals used in the different experiments.
Group EPM NSF LI-PE LI-NPE PPI
SAL/SERT+/+ 14 9 7 6 15
SAL/SERT+/− 22 11 9 9 13
VPA/SERT+/+ 12 10 6 6 12
VPA/SERT+/− 19 12 9 9 12
Total 67 42 31 30 52
for 2 consecutive days prior to the experiment. Rats were food
deprived 24 h after which they were placed next to the wall in a
circular open field (80 cm diameter, with 30 cm high walls), facing
the wall. A food pellet was placed in the center of the arena on a
small (6 cm diameter) circular piece of filter paper. The latency to
start eating was taken as the dependent variable. When animals
failed to start eating within 10 min, they were removed from the
open field and the analysis. In total 42 rats were included in the
analysis (see Table 1).
Latent Inhibition
Latent inhibition (LI) is often used to assess selective attention
(Lubow, 1989) and is based on the phenomenon that
conditioning of a stimulus is retarded when that stimulus
has previously been presented repeatedly without any direct
consequences. In the present experiment we used the conditioned
taste aversion protocol to assess LI (Ellenbroek et al., 1997).
For this experiment, rats were singly housed for 24 h before
the start of the experiment with water bottles removed. For 3
consecutive days rats were given a single bottle with either tap
water (non-pre-exposed) or a 5% sucrose solution (pre-exposed)
for 30 min and the total volume consumed was recorded. On
the fourth day all rats were given 30min access to a 5% sucrose
solution after which they were intraperitoneally injected with 75
mg/kg lithium chloride (10mg/ml, Sigma-Aldrich, Auckland,
NZ). On the fifth and final day all animals were given a 30
min free access to one bottle of tap water and one bottle of 5%
sucrose. The dependent variable was the percentage of sucrose
over tap water consumed on the final day. In total 61 rats were
used (see Table 1).
Prepulse Inhibition
Prepulse inhibition (PPI) is used to assess information
processing, in particular sensorimotor gating (Braff and
Geyer, 1990). PPI was assessed using San Diego Instrument
startle equipment as previously described (Ellenbroek et al.,
1995, 1996). The startle chamber consisted of a Plexiglas tube
(diameter 8.2 cm, length 25 cm), placed in a sound-attenuated
chamber, in which the rats were individually placed. The tube
was mounted on a plastic frame, under which a piezoelectric
accelerometer was mounted, which recorded and transduced the
motion of the tube. After the rats were placed into the chamber,
they were allowed to habituate for a period of 5 min during which
a 70 dB[A] background noise was present. After this period the
rats were exposed to five startle stimuli (120 dB[A], 20ms in
duration), followed by a series of startle and prepulse inhibition
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trials. Prepulse inhibition trials consisted of a prepulse (72, 74,
78 or 86 dB[A] intensity, 20ms duration) followed 100ms later
by the same 120 dB[A] startle stimulus. The session ended with
another block of five 120 dB[A] startle trials. The inter-trial
interval was pseudorandom between 10 and 20 s, and the entire
session lasted for about 17min. The resulting movement of the
rat in the startle chamber was measured during 100 ms after
startle stimulus onset (sampling frequency 1 kHz), rectified,
amplified and fed into a computer, which calculated the maximal
response over the 100-ms period. Basal startle amplitude was
determined as the mean amplitude of the 10 startle trials
that were interspersed with the first prepulse inhibition trials.
Prepulse inhibition was calculated according to the formula
100 × [1 – (PPx/P120)], in which PPx is the mean of the 10
prepulse inhibition trials (PP72, PP74, PP78 or PP86), and P120
is the basal startle amplitude. Percentage startle habituation was
calculated as 100∗P120l/P120f, with P120f, and P120l being the
average of the first and the last five startle responses, respectively.
Statistical Analysis
Data were statistically evaluated using SPSS Statistics v20 using
two or three way factorial Analysis of Variance (ANOVA) with
p < 0.05 considered statistically significant. More details can be
found in the results section of each experiment.
RESULTS
EPM
The results of the EPM are displayed in Figure 1 and were
analyzed with a two way ANOVA with prenatal treatment and
genotype as between subject factors. Both the time spent in the
open arm [Figure 1A, F(1, 61) = 12.8, p< 0.001] and in the closed
arm [Figure 1B, F(1, 61) = 5.1, p < 0.05] showed a significant
prenatal treatment effect, with VPA decreasing the time spent in
the open arms (and subsequently increasing the time spent in the
closed arms). However, there was no significant genotype effect,
nor any interactions between genotype and prenatal treatment.
The total distance moved and the average speed did not differ
between the groups (see Table 2). The frequency of stretched
attend posture is displayed in Figure 1C. A two way ANOVA
identified a significant treatment effects [F(1, 61) = 18.9, p <
0.001], while the genotype [F(1, 61) = 0.21, ns]and interaction
[F(1, 61) = 1.43, ns]were not significant.
NSF
The latency to start feeding in the NSF test are displayed in
Figure 2. A twowayANOVA found a significant effect of prenatal
treatment [F(1, 38) = 5.2, p < 0.05], but not a genotype effect
[F(1, 38) = 0.2, ns] nor a significant interaction [F(1, 38) = 2.3, p=
0.12]. Inspection of the figure shows that prenatal VPA exposure
significantly increased the latency to eat.
LI
Figure 3 shows the results of the LI experiments, which were
statistically analyzed using a three way ANOVA, with prenatal
treatment, genotype and exposure to sucrose as between subject
factors. The analysis showed significant effects of exposure
FIGURE 1 | The effects of prenatal saline or valproate exposure in
wildtype (SERT+/+) and heterozygous SERT knockout (SERT+/−) rats
on the elevated plus maze. (A) Time (s) spent in the open arms; (B) Time (s)
spent in the closed arms; (C) Frequency of stretched attend posture.
Represented are the mean values plus Standard Error of the Mean. The
number of animals in each group is shown in Table 1. Data were analyzed
with a two way ANOVA with prenatal treatment and genotype as between
subject factors.
[F(1, 52) = 20.2, p < 0.001] and of prenatal treatment [F(1, 52)
= 6.3, p < 0.02]. In addition, there was a tendency for a
genotype effect [F(1, 52) = 3.5, p = 0.06] as well as a significant
genotype ∗ exposure interaction [F(1, 52) = 3.9, p = 0.05]. As
indicated in figure 3, valproate treatment significantly increased
sucrose consumption. We subsequently split the data according
to genotype and found that while VPA increased sucrose
consumption in SERT+/+ rats [F(1, 20) = 5.3, p < 0.05], this was
not seen in SERT+/− rats [F(1, 32) = 3.2, p = 0.08]. Interestingly,
a close look at figure 3 shows that, in contrast to all others groups,
the VPA/SERT+/− group did not show significant LI effect (i.e.,
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TABLE 2 | Total distance traveled and speed in the EPM.
Group Distance traveled (cm) Speed
Mean S.E.M. Mean S.E.M.
SAL/SERT+/+ 1472.7 83.0 5.00 0.27
SAL/SERT+/− 1414.2 57.6 4.75 0.19
VPA/SERT+/+ 1322.0 144.1 4.70 0.55
VPA/SERT+/− 1597.2 115.7 5.42 0.41
Represented are averages plus S.E.M. Data were analyzed with a two way ANOVA with
prenatal treatment and genotype as between subject factors.
FIGURE 2 | The effects of prenatal saline or valproate exposure in
wildtype (SERT+/+) and heterozygous SERT knockout (SERT+/−) rats
on the novelty suppressed feeding task. Represented are the mean
latency to start eating plus Standard Error of the Mean. The number of animals
in each group is shown in Table 1. Data were analyzed with a two way ANOVA
with prenatal treatment and genotype as between subject factors.
no statistically significant differences between pre- and non-
pre-exposed animals), although the overall interaction failed to
reach significance.
PPI
Figure 4A shows the basal startle amplitude of rats prenatally
treated with either saline or VPA. Neither the genotype [F(1, 51)
= 0.6, p > 0.4] nor the prenatal treatment effects was significant
[F(1, 51) = 1.9, p = 0.17]. While there was a significant within-
subject effect of prepulse intensity, there were no 2 or 3
way interactions between prepulse intensity, genotype and/or
prenatal treatment (data not shown). Therefore, we collapsed
all prepulse intensities into a single prepulse inhibition value
(Figure 4B). Two way ANOVA revealed a significant effect of
prenatal treatment [F(1, 51) = 5.1, p < 0.05] with reduced PPI
in the valporate group, but there was no effect of genotype
nor an interaction. Startle habituation, on the other hand (see
Figure 4C), was not significantly affected by either genotype or
prenatal treatment.
DISCUSSION
Valproic acid (VPA) is a well-established risk factor for the
development of ASD in humans (Christensen et al., 2013), and
FIGURE 3 | The effects of prenatal saline or valproate exposure in
wildtype (SERT+/+) and heterozygous SERT knockout (SERT+/−) rats
on the latent inhibition. Represented is the % sucrose consumption on the
final day for both the animals pre-exposed and non-preexposed to sucrose for
3 days prior to conditioning. Represented are the mean values plus Standard
Error of the Mean. The number of animals in each group is shown in Table 1.
Data were analyzed with a three way ANOVA with prenatal treatment,
genotype and pre-exposure as between subject factors.
subsequently, multiple studies in mice and rats have shown that
a single injection of VPA to pregnant dams can induce ASD-
like symptoms. These include deficits in the core aspects of ASD:
social behavior, communication and stereotypy (Schneider et al.,
2008; Roullet et al., 2013; Ranger and Ellenbroek, 2015), although
differences exist between individual studies in relation to dose,
route and timing of administration as well as species. In line with
our current results, valproate has also been found to increase
anxiety (Schneider et al., 2008; Mehta et al., 2011), and decrease
PPI (Schneider and Przewlocki, 2005), although the latter is not
uniformly found (Dendrinos et al., 2011). To the best of our
knowledge, this paper is the first to evaluate the effect of VPA
in a model of LI. Deficits in cognition have also been previously
reported in rats prenatally exposed to VPA, including reduced
alterations in the Y-maze (Markram et al., 2008), and alterations
in the Morris water maze (Frisch et al., 2009). Given that there
was no significant interaction between prenatal treatment and
sucrose pre-exposure, the significant effect of VPA needs to be
interpreted as an overall impairment in conditioning as seen in
the global increase in sucrose consumption (see Figure 3), rather
than a specific decrease in LI.
Both the EPM and the NSF showed that prenatal VPA
increased anxiety-like behavior, as seen by a decrease in time
spent in the open arms in the EPM and an increase in the
latency to start feeding in the NSF. Importantly, in the EPM there
was no influence of VPA treatment on total distance traveled
or average speed, suggesting that the observed differences in
time spent are not secondary to differences in exploratory
behavior. Intriguingly, we found that VPA significantly reduced
the frequency of stretched attend posture (as well as the total
duration, data not shown). This was unexpected as stretched
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FIGURE 4 | The effects of prenatal saline or valproate exposure in
wildtype (SERT+/+) and heterozygous SERT knockout (SERT+/−) rats
on acoustic startle responding. (A) Basal startle amplitude; (B) Percentage
prepulse inhibition; (C) Percentage habituation. Represented are the mean
values plus Standard Error of the Mean. The number of animals in each group
is shown in Table 1. Data were analyzed with a two way ANOVA with prenatal
treatment and genotype as between subject factors.
attend posture is usually considered a sign of anxiety. Thus,
in most studies a decrease in time spent in the open arms
is accompanied by an increase in stretched attend postures
(Cole and Rodgers, 1994; De Almeida et al., 1998; Fodor et al.,
2016). However, a more detailed analysis suggests that stretched
attention and time spent on the open arm are not necessarily
strongly related to each other. For instance, Semaphorin 5a
mutant mice (proposed as another animal model for ASD)
show no difference in time spent on the open arms but a
significantly increased frequency of stretched attend posture
(Gunn et al., 2011). Perhaps more importantly, in a detailed
analysis of anxiety like behavior in mice strains, factor analysis
showed that stretched attend postures and time spent on the
open arms loaded on independent factors (O’leary et al., 2013).
In a similar vein, an analysis of the Roman high and low
avoidance strains found that while differences in stretched
attend postures were predictive of performance in an active
avoidance paradigm, frequency of open arm entry was predictive
of fear potentiated startle. Together these data suggest that the
relationship between these two variables is far from clear and
it has indeed been suggested that a stretched attend posture is
more related to risk-assessment than to anxiety per se. Analysing
risks in a novel environment is a crucial part in survival
in both animals and humans with a complicated interaction
between emotion (anxiogenic environment) and cognition (risk
assessment). Hence, it might be speculated that decreased
stretch posture might indicate an impairment in attention and
active exploration required in successful adaptation to a novel
surroundings. This is reminiscent of the less active engagement
with stimuli and insistence on sameness in a novel environment
in autistic children (Eisenberg et al., 2015).
The current study found virtually no genotype effects, except
for a tendency in the LI experiment (p = 0.06). Although this
might be somewhat surprising, given the role 5-HT and the
SERT play in, especially, anxiety, it is important to keep in
mind that we used rats heterozygous for the SERT ablation.
Previous experiments from our lab found that homozygous SERT
knock out rats show a significant decrease in time spent on the
open arms of the elevated plus maze as well as an increased
latency to start feeding in the novelty suppressed feeding task
(Olivier et al., 2008), consistent with an anxious phenotype. A
reduction in latent inhibition has also previously been reported
for homozygous SERT knock out rats (Nonkes et al., 2012), which
was thought to be, at least in part, responsible for the increased
performance in a set-shifting task. Previous research from our
group has implicated the basal ganglia in latent inhibition
as measured using the conditioned taste aversion paradigm
(Ellenbroek et al., 1997), although other structures, including
part of the prefrontal cortex are also likely involved (Nonkes
et al., 2012). Pharmacologically, most studies on latent inhibition
have focussed on dopamine (Moser et al., 2000). There is also
evidence that 5-HT is involved, although the exact mechanism
is unclear (Moser et al., 2000). Thus, while both 5-HT1A and 5-
HT3 receptor antagonists facilitate LI (Warburton et al., 1994;
Killcross et al., 1997), selective serotonin reuptake inhibitors
induce the same effect (Moser et al., 2000), thus suggesting a
complicated relationship between serotonin transmission and LI.
Interestingly, none of the experiments of the current series
found a significant gene–environment interaction. Inspection of
Figure 3 suggests that in contrast to all groups, the SERT+/−
rats prenatally treated with valproate did not show a significant
LI (indeed this group was the only one that did not show
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a significant difference between the pre-exposed and non-pre-
exposed). However, as the prenatally saline treated SERT+/−
group also had a smaller LI, compared to SERT+/+ group, the
interaction did not reach significance.
The lack of any significant gene–environment interaction is
surprising, given the prominent role 5-HT plays in ASD as well
as the studies in rats and mice that have shown that prenatal
valproate affects the serotonergic system. Previous studies have
shown that prenatal valproate increases 5-HT levels in the
frontal cortex (Narita et al., 2002; Tsujino et al., 2007) and
decreases these levels in the hippocampus (Dufour-Rainfray
et al., 2010), while not altering SERT levels within the brain
(Dufour-Rainfray et al., 2010). Intriguingly, studies have also
found a significant effect of VPA on 5-HT development, with
prenatal VPA treatment leading to a caudal shift in 5-HT cell
bodies within the brain (Miyazaki et al., 2005). In vitro research
suggests that this may be due to a retarded neuronal maturation,
possibly mediated via an effect on Sonic Hedgehog (a protein
involved in serotonergic development). Subsequent studies from
the same group confirmed a reduction in mRNA for Sonic
Hedgehog at GD11.5, associated with an abnormal distribution
of 5-HT neurons in the caudal rostral raphe nucleus (Oyabu et al.,
2013).
These convincing biochemical and morphological data beg
the question why we failed to find (strong) evidence for a gene–
environment interaction. Several different possible explanations
can be put forward. The most parsimonious explanation is that
these biochemical findings simply do not translate into ASD-
like behavioral symptoms. However, this seems unlikely given the
strong association between 5-HT alterations and ASD symptoms
in humans (Lam et al., 2006). Moreover, rats and mice with a
complete lack of the SERT show ASD-like features (Homberg
et al., 2007b; Moy et al., 2009). Likewise, transgenic mice with
another point mutation in the SERT (Ala56, also leading to
hyperserotonemia), also show deficits in the core symptoms of
ASD (Veenstra-Vanderweele et al., 2012). Finally, as mentioned
in the introduction, there is increasing evidence that prenatal
SSRI treatment can induce ASD in humans. Thus, there is
ample evidence that excess 5-HT, especially during development,
can induce ASD-like symptoms in humans as well as in
rodents.
A second explanation could be that perhaps the interaction
between VPA and enhanced 5-HT levels is relevant for the core
but not the auxiliary symptoms of ASD. Although this is possible,
and we are currently evaluating the interaction model in relation
to social behavior, communication and stereotypy, we specifically
focussed on cognition and anxiety in this paper because of the
clear link with 5-HT. Indeed, homozygous SERT KO rats and
mice show increased anxiety-like behavior (Holmes et al., 2003;
Olivier et al., 2008), as do rats and mice prenatally treated SSRIs
(Olivier et al., 2011). Although less well studied, there is also
evidence for cognitive alterations in (homozygous) SERT knock-
out rats (Nonkes and Homberg, 2013), including a reduction in
LI (Nonkes et al., 2012). Considering the notorious heterogeneity
of ASD symptomatology in humans and the fact that cognitive
and anxiety symptoms (in contrast to the core deficits) are not
seen in all patients with ASD (Levy et al., 2009), it is still possible
that we may find significant interactions with other aspects of
ASD.
A third possible explanation for failing to find a significant
gene–environment interaction would be the presence of a ceiling
or floor effect. Theoretically, if either of the two factors, by
themselves, already show a strong effect, a further increase in
this effect by the second factor might not be possible. Again,
this seems an unlikely explanation given the fact that we
purposely used a relatively moderate dose of VPA combined
with heterozygous SERT knock-out rats. Moreover, inspection
of the figures shows that, when there was a significant effect of
VPA treatment, this effect was only moderate, leaving room for a
moderation by the genotype.
The final, and perhaps most likely, explanation for the lack
of an interaction effect is related to the issue of timing. In
the current set of experiments, VPA was injected at GD12,
in line with most other studies that have been performed in
rodent models relating to ASD (Schneider and Przewlocki,
2005; Roullet et al., 2013; Ranger and Ellenbroek, 2015), and
consistent with findings that similar injections on GD7, 9 or
15 were significantly less effective in changing sociability and
in seizure threshold (Kim et al., 2011). However, the studies
that have investigated alterations in 5-HT neurodevelopment
and functioning have all applied VPA at GD9 (Miyazaki
et al., 2005; Tsujino et al., 2007; Dufour-Rainfray et al.,
2010; Oyabu et al., 2013). Together this might suggest that
while in normal animals GD12 is the optimal time for
inducing ASD-like symptoms, GD9 might be more optimal
for rats with a compromised 5-HT system. Although so far
we have no evidence for this hypothesis, it would be in
line with multiple other studies showing that the timing of
early adverse environmental factors crucially determines the
long term outcome. For example, within the human literature,
research investigating the effects of the Dutch famine in
1944/1945 (Kyle and Pichard, 2006), of bereavement (Class et al.,
2014) and of hurricane exposure (Kinney et al., 2008a) on
psychopathology show clear time-dependent effects. Likewise,
studies from our own laboratory have shown that the long term
consequences of maternal deprivation (Ellenbroek and Riva,
2003) or prenatal exposure to lipopolysaccharide (Waterhouse
et al., 2016) critically depend on the timing of the environmental
insult. Thus, this leads to the exiting idea that the nature
of the gene ∗ environmental interaction is also governed
by the specific timing of the environmental factor. Future
research will obviously be necessary to further investigate this
hypothesis.
In summary, in the present paper we set out to investigate
whether prenatal exposure to VPA at GD12 increased anxiety
and disrupted cognitive processes and whether this effect was
enhanced in rats with a genetically compromised serotonergic
system. We found clear evidence for the first: an increase in
anxiety in both the elevated plus maze and the novelty suppressed
feeding and a decrease in cognition as evidenced by a reduction
in sucrose intake in the latent inhibition task and in prepulse
inhibition. However, we failed to find strong support for a gene–
environment interaction and we have discussed that this may be
related to the timing of the VPA injection.
Frontiers in Neuroscience | www.frontiersin.org 7 September 2016 | Volume 10 | Article 424
Ellenbroek et al. Prenatal Valproate and SERT KO Rats
AUTHOR CONTRIBUTIONS
BE was involved in the planning of the experiments, analysing
the data and wrote the majority of the paper. CA performed the
experiments, analyzed the data and was involved in the writing
of the paper. JY was involved in the analysis of the data and in
writing the paper.
ACKNOWLEDGMENTS
The authors wish to thank Michael Roberts for his
excellent help in maintaining the animal colony and
the members of the Behavioral Neurogenetics group
(www.behaviouralneurogenetics.com) for their valuable
comments and critical insight.
REFERENCES
Abdallah, M. W., Hougaard, D. M., Norgaard-Pedersen, B., Grove, J., Bonefeld-
Jorgensen, E. C., and Mortensen, E. L. (2012). Infections during pregnancy and
after birth, and the risk of autism spectrum disorders: a register-based study
utilizing a danish historic birth cohort. Turk Psikiyatri Derg. 23, 229–236. doi:
10.5080/u6847
Atladottir, H. O., Thorsen, P., Ostergaard, L., Schendel, D. E., Lemcke, S., Abdallah,
M., et al. (2010). Maternal infection requiring hospitalization during pregnancy
and autism spectrum disorders. J. Autism Dev. Disord. 40, 1423–1430. doi:
10.1007/s10803-010-1006-y
Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D., et al.
(2006). Prevalence of disorders of the autism spectrum in a population cohort
of children in South Thames: the Special Needs and Autism Project (SNAP).
Lancet 368, 210–215. doi: 10.1016/S0140-6736(06)69041-7
Bambini-Junior, V., Rodrigues, L., Behr, G. A., Moreira, J. C., Riesgo, R., and
Gottfried, C. (2011). Animal model of autism induced by prenatal exposure to
valproate: behavioral changes and liver parameters. Brain Res. 1408, 8–16. doi:
10.1016/j.brainres.2011.06.015
Banerjee-Basu, S., and Packer, A. (2010). SFARI Gene: an evolving database
for the autism research community. Dis. Model. Mech. 3, 133–135. doi:
10.1242/dmm.005439
Braff, D. L., and Geyer, M. A. (1990). Sensorimotor gating and schizophrenia.
Hum. Anim. Model. Stud. Arch. Gen. Psychiatry 47, 181–188. doi:
10.1001/archpsyc.1990.01810140081011
Bromley, R. L., Mawer, G., Clayton-Smith, J., and Baker, G. A. (2008). Autism
spectrum disorders following in utero exposure to antiepileptic drugs.
Neurology 71, 1923–1924. doi: 10.1212/01.wnl.0000339399.64213.1a
Buescher, A. V., Cidav, Z., Knapp, M., and Mandell, D. S. (2014). Costs of autism
spectrum disorders in the United Kingdom and the United States. JAMA
Pediatr. 168, 721–728. doi: 10.1001/jamapediatrics.2014.210
Christensen, J., Gronborg, T. K., Sorensen, M. J., Schendel, D., Parner, E.
T., Pedersen, L. H., et al. (2013). Prenatal valproate exposure and risk of
autism spectrum disorders and childhood autism. JAMA 309, 1696–1703. doi:
10.1001/jama.2013.2270
Class, Q. A., Abel, K. M., Khashan, A. S., Rickert, M. E., Dalman, C., Larsson,
H., et al. (2014). Offspring psychopathology following preconception, prenatal
and postnatal maternal bereavement stress. Psychol. Med. 44, 71–84. doi:
10.1017/S0033291713000780
Cole, J. C., and Rodgers, R. J. (1994). Ethological evaluation of the effects of
acute and chronic buspirone treatment in the murine elevated plus-maze test:
comparison with haloperidol. Psychopharmacology (Berl). 114, 288–296. doi:
10.1007/BF02244851
De Almeida, R. M., Giovenardi, M., Charchat, H., and Lucion, A. B. (1998). 8-OH-
DPAT in the median raphe nucleus decreases while in the medial septal area it
may increase anxiety in female rats. Neurosci. Biobehav. Rev. 23, 259–264. doi:
10.1016/S0149-7634(98)00026-8
Dendrinos, G., Hemelt, M., and Keller, A. (2011). Prenatal VPA exposure and
changes in sensory processing by the superior colliculus. Front. Integr. Neurosci.
5:68. doi: 10.3389/fnint.2011.00068
Dufour-Rainfray, D., Vourc’h, P., Le Guisquet, A. M., Garreau, L., Ternant, D.,
Bodard, S., et al. (2010). Behavior and serotonergic disorders in rats exposed
prenatally to valproate: a model for autism. Neurosci. Lett. 470, 55–59. doi:
10.1016/j.neulet.2009.12.054
Eisenberg, I. W., Wallace, G. L., Kenworthy, L., Gotts, S. J., and Martin, A. (2015).
Insistence on sameness relates to increased covariance of gray matter structure
in autism spectrum disorder. Mol. Autism 6, 54. doi: 10.1186/s13229-015-
0047-7
Ellenbroek, B. A., Geyer, M. A., and Cools, A. R. (1995). The behavior of APO-SUS
rats in animal models with construct validity for schizophrenia. J. Neurosci. 15,
7604–7611.
Ellenbroek, B. A., Knobbout, D. A., and Cools, A. R. (1997). The role of
mesolimbic and nigrostriatal dopamine in latent inhibition as measured with
the conditioned taste aversion paradigm. Psychopharmacology (Berl). 129,
112–120. doi: 10.1007/s002130050170
Ellenbroek, B. A., Lubbers, L. J., and Cools, A. R. (1996). Activity of “seroquel”
(ICI 204,636) in animal models for atypical properties of antipsychotics:
a comparison with clozapine. Neuropsychopharmacology 15, 406–416. doi:
10.1016/0893-133X(96)00001-2
Ellenbroek, B., and Riva, M. (2003). Early maternal deprivation as an animal
model for schizophrenia. Clin. Neurosci. Res. 3, 297–302. doi: 10.1016/S1566-
2772(03)00090-2
Fodor, A., Kovacs, K. B., Balazsfi, D., Klausz, B., Pinter, O., Demeter, K., et al.
(2016). Depressive- and anxiety-like behaviors and stress-related neuronal
activation in vasopressin-deficient female Brattleboro rats. Physiol. Behav. 158,
100–111. doi: 10.1016/j.physbeh.2016.02.041
Frisch, C., Husch, K., Angenstein, F., Kudin, A., Kunz,W., Elger, C. E., et al. (2009).
Dose-dependent memory effects and cerebral volume changes after in utero
exposure to valproate in the rat. Epilepsia 50, 1432–1441. doi: 10.1111/j.1528-
1167.2008.01943.x
Gauglerl, T., Klei, L., Sanders, S. J., Bodea, C. A., Goldberg, A. P., Lee, A. B., et al.
(2014). Most genetic risk for autism resides with common variation.Nat. Genet.
46, 881–885. doi: 10.1038/ng.3039
Gunn, R. K., Huentelman, M. J., and Brown, R. E. (2011). Are Sema5amutant mice
a good model of autism? A behavioral analysis of sensory systems, emotionality
and cognition. Behav. Brain Res. 225, 142–150. doi: 10.1016/j.bbr.2011.
07.008
Hansen, S. N., Schendel, D. E., and Parner, E. T. (2015). Explaining the
increase in the prevalence of autism spectrum disorders the proportion
attributable to changes in reporting practices. JAMA Pediatr. 169, 56–62. doi:
10.1001/jamapediatrics.2014.1893
Hecht, P. M., Hudson, M., Connors, S. L., Tilley, M. R., Liu, X., and Beversdorf,
D. Q. (2016). Maternal serotonin transporter genotype affects risk for
ASD with exposure to prenatal stress. Autism Res. doi: 10.1002/aur.1629.
[Epub ahead of print].
Holmes, A., Murphy, D. L., and Crawley, J. N. (2003). Abnormal behavioral
phenotypes of serotonin transporter knockout mice: parallels with
human anxiety and depression. Biol. Psychiatry 54, 953–959. doi:
10.1016/j.biopsych.2003.09.003
Homberg, J. R., Olivier, J. D. A., Smits, B. M. G., Mul, J. D., Mudde, J., Verheul,
M., et al. (2007a). Characterization of the serotonin transporter knockout rat:
a selective change in the functioning of the serotonergic system. Neuroscience
146, 1662–1676. doi: 10.1016/j.neuroscience.2007.03.030
Homberg, J. R., Schiepers, O. J., Schoffelmeer, A. N., Cuppen, E., and
Vanderschuren, L. J. (2007b). Acute and constitutive increases in central
serotonin levels reduce social play behaviour in peri-adolescent rats.
Psychopharmacology (Berl). 195, 175–182. doi: 10.1007/s00213-007-0895-8
Kenna, G. A., Roder-Hanna, N., Leggio, L., Zywiak, W. H., Clifford, J.,
Edwards, S., et al. (2012). Association of the 5-HTT gene-linked promoter
region (5-HTTLPR) polymorphism with psychiatric disorders: review of
psychopathology and pharmacotherapy. Pharmgenomics. Pers. Med. 5, 19–35.
doi: 10.2147/pgpm.s23462
Frontiers in Neuroscience | www.frontiersin.org 8 September 2016 | Volume 10 | Article 424
Ellenbroek et al. Prenatal Valproate and SERT KO Rats
Kielinen, M., Linna, S. L., and Moilanen, I. (2000). Autism in Northern Finland.
Eur. Child Adolesc. Psychiatry 9, 162–167. doi: 10.1007/s007870070039
Killcross, A. S., Stanhope, K. J., Dourish, C. T., and Piras, G. (1997). WAY100635
and latent inhibition in the rat: selective effects at preexposure. Behav. Brain
Res. 88, 51–57. doi: 10.1016/S0166-4328(97)02309-7
Kim, K. C., Kim, P., Go, H. S., Choi, C. S., Yang, S. I., Cheong, J. H., et al.
(2011). The critical period of valproate exposure to induce autistic symptoms
in Sprague-Dawley rats. Toxicol. Lett. 201, 137–142. doi: 10.1016/j.toxlet.2010.
12.018
Kim, Y. S., and Leventhal, B. L. (2015). Genetic epidemiology and insights into
interactive genetic and environmental effects in autism spectrum disorders.
Biol. Psychiatry 77, 66–74. doi: 10.1016/j.biopsych.2014.11.001
Kinney, D. K., Miller, A. M., Crowley, D. J., Huang, E., and Gerber, E. (2008a).
Autism prevalence following prenatal exposure to hurricanes and tropical
storms in Louisiana. J. Autism Dev. Disord. 38, 481–488. doi: 10.1007/s10803-
007-0414-0
Kinney, D. K., Munir, K. M., Crowley, D. J., and Miller, A. M. (2008b). Prenatal
stress and risk for autism. Neurosci. Biobehav. Rev. 32, 1519–1532. doi:
10.1016/j.neubiorev.2008.06.004
Kyle, U. G., and Pichard, C. (2006). The Dutch Famine of 1944-
1945: a pathophysiological model of long-term consequences of
wasting disease. Curr. Opin. Clin. Nutr. Metab. Care 9, 388–394. doi:
10.1097/01.mco.0000232898.74415.42
Lam, K. S., Aman, M. G., and Arnold, L. E. (2006). Neurochemical correlates of
autistic disorder: a review of the literature. Res. Dev. Disabil. 27, 254–289. doi:
10.1016/j.ridd.2005.03.003
Lecouteur, A., Bailey, A., Goode, S., Pickles, A., Robertson, S., Gottesman, I., et al.
(1996). A broader phenotype of autism: the clinical spectrum in twins. J. Child
Psychol. Psychiatry 37, 785–801. doi: 10.1111/j.1469-7610.1996.tb01475.x
Levy, S. E., Mandell, D. S., and Schultz, R. T. (2009). Autism. Lancet 374,
1627–1638. doi: 10.1016/S0140-6736(09)61376-3
Lubow, R. E. (1989). Latent Inhibition and Conditoned Attention Theory. New
York, NY: Cambridge Univ. Press.
Malm, H., Brown, A. S., Gissler, M., Gyllenberg, D., Hinkka-Yli-Salomaki, S.,
Mckeague, I. W., et al. (2016). Gestational exposure to selective serotonin
reuptake inhibitors and offspring psychiatric disorders: a national register-
based study. J. Am. Acad. Child Adolesc. Psychiatry 55, 359–366. doi:
10.1016/j.jaac.2016.02.013
Man, K. K. C., Chan, E. W., Coghill, D. R., Ip, P., Simonoff, E., Lau, W. C. Y.,
et al. (2015). Prenatal antidepressant exposure and the risk of autism spectrum
disorder and attention-deficit hyperactivity disorder. Pharmacoepidemiol. Drug
Saf. 24, 234–234. doi: 10.1002/pds.3838
Markram, K., Rinaldi, T., La Mendola, D., Sandi, C., and Markram, H. (2008).
Abnormal fear conditioning and amygdala processing in an animal model
of autism. Neuropsychopharmacology 33, 901–912. doi: 10.1038/sj.npp.13
01453
Mehta, M. V., Gandal, M. J., and Siegel, S. J. (2011). mGluR5-antagonist mediated
reversal of elevated stereotyped, repetitive behaviors in the VPA model of
autism. PLoS ONE 6:e26077. doi: 10.1371/journal.pone.0026077
Miyazaki, K., Narita, N., and Narita, M. (2005). Maternal administration of
thalidomide or valproic acid causes abnormal serotonergic neurons in the
offspring: implication for pathogenesis of autism. Int. J. Dev. Neurosci. 23,
287–297. doi: 10.1016/j.ijdevneu.2004.05.004
Moore, S. J., Turnpenny, P., Quinn, A., Glover, S., Lloyd, D. J., Montgomery,
T., et al. (2000). A clinical study of 57 children with fetal anticonvulsant
syndromes. J. Med. Genet. 37, 489–497. doi: 10.1136/jmg.37.7.489
Moser, P. C., Hitchcock, J. M., Lister, S., and Moran, P. M. (2000). The
pharmacology of latent inhibition as an animal model of schizophrenia. Brain
Res. Brain Res. Rev. 33, 375–307. doi: 10.1016/S0165-0173(00)00026-6
Moy, S. S., Nadler, J. J., Young, N. B., Nonneman, R. J., Grossman, A. W.,
Murphy, D. L., et al. (2009). Social approach in genetically engineered mouse
lines relevant to autism. Genes Brain Behav. 8, 129–142. doi: 10.1111/j.1601-
183X.2008.00452.x
Moy, S. S., Nadler, J. J., Young, N. B., Nonneman, R. J., Segall, S. K., Andrade,
G. M., et al. (2008). Social approach and repetitive behavior in eleven
inbred mouse strains. Behav. Brain Res. 191, 118–129. doi: 10.1016/j.bbr.2008.
03.015
Moy, S. S., Nadler, J. J., Young, N. B., Perez, A., Holloway, L. P., Barbaro, R. P.,
et al. (2007).Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred
strains. Behav. Brain Res. 176, 4–20. doi: 10.1016/j.bbr.2006.07.030
Narita, N., Kato, M., Tazoe, M., Miyazaki, K., Narita, M., and Okado, N.
(2002). Increased monoamine concentration in the brain and blood of fetal
thalidomide- and valproic acid-exposed rat: putative animal models for autism.
Pediatr. Res. 52, 576–579. doi: 10.1203/00006450-200210000-00018
Nijmeijer, J. S., Hartman, C. A., Rommelse, N. N., Altink, M. E., Buschgens, C.
J., Fliers, E. A., et al. (2010). Perinatal risk factors interacting with catechol O-
methyltransferase and the serotonin transporter gene predict ASD symptoms
in children with ADHD. J. Child Psychol. Psychiatry 51, 1242–1250. doi:
10.1111/j.1469-7610.2010.02277.x
Nonkes, L. J., and Homberg, J. R. (2013). Perseverative instrumental and Pavlovian
responding to conditioned stimuli in serotonin transporter knockout rats.
Neurobiol. Learn. Mem. 100, 48–55. doi: 10.1016/j.nlm.2012.12.004
Nonkes, L. J., Van De, V., Ii, De Leeuw, M. J., Wijlaars, L. P., Maes, J. H., and
Homberg, J. R. (2012). Serotonin transporter knockout rats show improved
strategy set-shifting and reduced latent inhibition. Learn. Mem. 19, 190–193.
doi: 10.1101/lm.025908.112
Nyffeler, J., Walitza, S., Bobrowski, E., Gundelfinger, R., and Grunblatt, E. (2014).
Association study in siblings and case-controls of serotonin- and oxytocin-
related genes with high functioning autism. J. Mol. Psychiatry 2:1. doi:
10.1186/2049-9256-2-1
O’leary, T. P., Gunn, R. K., and Brown, R. E. (2013). What are we measuring
when we test strain differences in anxiety in mice? Behav. Genet. 43, 34–50.
doi: 10.1007/s10519-012-9572-8
Olivier, J. D. A., Blom, T., Arentsen, T., and Homberg, J. R. (2011). The age-
dependent effects of selective serotonin reuptake inhibitors in humans and
rodents: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1400–1408.
doi: 10.1016/j.pnpbp.2010.09.013
Olivier, J. D. A., Van Der Hart, M. G. C., Van Swelm, R. P. L., Dederen, P. J.,
Homberg, J. R., Cremers, T., et al. (2008). A study in male and female 5-
HT transporter knockout rats: an animal model for anxiety and depression
disorders. Neuroscience 152, 573–584. doi: 10.1016/j.neuroscience.2007.12.032
Oyabu, A., Narita, M., and Tashiro, Y. (2013). The effects of prenatal exposure to
valproic acid on the initial development of serotonergic neurons. Int. J. Dev.
Neurosci. 31, 202–208. doi: 10.1016/j.ijdevneu.2013.01.006
Pellow, S., Chopin, P., File, S. E., and Briley, M. (1985). Validation of open - closed
arm entries in an elevated plus-maze as a measure of anxiety in the rat. J.
Neurosci. Methods 14, 149–167. doi: 10.1016/0165-0270(85)90031-7
Ranger, P., and Ellenbroek, B. A. (2015). Perinatal influences of valproate on brain
and behaviour: an animal model for autism. Curr. Top. Behav. Neurosci. 29,
363–386. doi: 10.1007/7854_2015_404
Rasalam, A. D., Hailey, H., Williams, J. H., Moore, S. J., Turnpenny, P. D.,
Lloyd, D. J., et al. (2005). Characteristics of fetal anticonvulsant syndrome
associated autistic disorder. Dev. Med. Child Neurol. 47, 551–555. doi:
10.1017/S0012162205001076
Raza, S., Himmler, B. T., Himmler, S. M., Harker, A., Kolb, B., Pellis, S. M.,
et al. (2015). Effects of prenatal exposure to valproic acid on the development
of juvenile-typical social play in rats. Behav. Pharmacol. 26, 707–719. doi:
10.1097/FBP.0000000000000169
Roullet, F. I., Lai, J. K., and Foster, J. A. (2013). In utero exposure to valproic
acid and autism–a current review of clinical and animal studies. Neurotoxicol.
Teratol. 36, 47–56. doi: 10.1016/j.ntt.2013.01.004
Sandin, S., Lichtenstein, P., Kuja-Halkola, R., Larsson, H., Hultman, C. M., and
Reichenberg, A. (2014). The Familial Risk of Autism. JAMA 311, 1770–1777.
doi: 10.1001/jama.2014.4144
Schneider, T., and Przewlocki, R. (2005). Behavioral alterations in rats prenatally
exposed to valproic acid: animal model of autism. Neuropsychopharmacology
30, 80–89. doi: 10.1038/sj.npp.1300518
Schneider, T., Roman, A., Basta-Kaim, A., Kubera, M., Budziszewska, B.,
Schneider, K., et al. (2008). Gender-specific behavioral and immunological
alterations in an animal model of autism induced by prenatal
exposure to valproic acid. Psychoneuroendocrinology 33, 728–740. doi:
10.1016/j.psyneuen.2008.02.011
Smits, B. M. G., Mudde, J. B., Van De Belt, J., Verheul, M., Olivier, J., Homberg,
J., et al. (2006). Generation of gene knockouts and mutant models in the
Frontiers in Neuroscience | www.frontiersin.org 9 September 2016 | Volume 10 | Article 424
Ellenbroek et al. Prenatal Valproate and SERT KO Rats
laboratory rat by ENU-driven target-seletted mutagenesis. Pharmacogenet.
Genomics 16, 159–169. doi: 10.1097/01.fpc.0000184960.82903.8f
Tsujino, N., Nakatani, Y., Seki, Y., Nakasato, A., Nakamura, M., Sugawara, M., et al.
(2007). Abnormality of circadian rhythm accompanied by an increase in frontal
cortex serotonin in animal model of autism. Neurosci. Res. 57, 289–295. doi:
10.1016/j.neures.2006.10.018
Veenstra-Vanderweele, J., Muller, C. L., Iwamoto, H., Sauer, J. E., Owens, W.
A., Shah, C. R., et al. (2012). Autism gene variant causes hyperserotonemia,
serotonin receptor hypersensitivity, social impairment and repetitive behavior.
Proc. Natl. Acad. Sci. U.S.A. 109, 5469–5474. doi: 10.1073/pnas.1112345109
Warburton, E. C., Joseph, M. H., Feldon, J., Weiner, I., and Gray, J. A. (1994).
Antagonism of amphetamine-induced disruption of latent inhibition in rats
by haloperidol and ondansetron: implications for a possible antipsychotic
action of ondansetron. Psychopharmacology (Berl). 114, 657–664. doi:
10.1007/BF02244998
Warrier, V., Chee, V., Smith, P., Chakrabarti, B., and Baron-Cohen, S. (2015). A
comprehensive meta-analysis of common genetic variants in autism spectrum
conditions.Mol. Autism 6:49. doi: 10.1186/s13229-015-0041-0
Waterhouse, U., Rpoer, V. E., Brennan, K. A., and Ellenbroek, B. A.
(2016). Nicotine ameliorates cognitive deficits induced by maternal LPS
exposure: a study in rats. Dis. Models Mech. doi: 10.1242/dmm.025072.
[Epub ahead of print].
Weiss, E. M., Schulter, G., Fink, A., Reiser, E. M., Mittenecker, E., Niederstatter, H.,
et al. (2014). Influences of COMT and 5-HTTLPR polymorphisms on cognitive
flexibility in healthy women: inhibition of prepotent responses and memory
updating. PloS ONE 9:e85506. doi: 10.1371/journal.pone.0085506
Williams, K., Macdermott, S., Ridley, G., Glasson, E. J., andWray, J. A. (2008). The
prevalence of autism in Australia. Can it be established from existing data? J.
Paediatr. Child Health 44, 504–510. doi: 10.1111/j.1440-1754.2008.01331.x
Zurcher, N. R., Bhanot, A., Mcdougle, C. J., and Hooker, J. M. (2015). A systematic
review of molecular imaging (PET and SPECT) in autism spectrum disorder:
current state and future research opportunities. Neurosci. Biobehav. Rev. 52,
56–73. doi: 10.1016/j.neubiorev.2015.02.002
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Ellenbroek, August and Youn. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 10 September 2016 | Volume 10 | Article 424
